US authorities weigh whether to resume J&J vaccine use

New guidance is expected after a government advisory panel deliberates on a link between the shot and rare blood clots.

With the United States pause of Johnson & Johnson’s COVID-19 vaccine stretched into a second week, authorities are weighing whether to resume the shots the way European regulators decided to – with warnings of a “very rare” risk. New guidance is expected late on Friday after a government advisory panel deliberates a possible link between J&J’s shot and a handful of vaccine recipients who developed highly unusual blood clots. The Centers for Disease Control and Prevention (CDC) is looking to its advisers to help determine how big any risk really is – and how to balance it with the need to vaccinate millions against a virus that is still infecting tens of thousands of Americans every day.